Abstract
The health of people is now seriously threatened by diabetes. Type 2 diabetes mellitus’ patients are prone to microvascular diseases, which is a cardiovascular disease risk factor. In T2DM patients, it has been demonstrated that sodium-glucose co-transporters (SGLT2) inhibitors have positive cardiovascular effects, glucagon like peptide 1 (GLP-1) receptor agonist also exhibited similar effect on cardiovascular. In recent, noteworthy trials, GLP-1RAs and SGLT-2Is have demonstrated effective cardiac protection and safety in high-risk T2DM patients, which is a new force in T2DM drug therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
